Biogen Inc

2026. g. 4. sept. 23:46 UTC

Biogen Inc shares are lower in after-market hours, with no specific news driving the decline. Broader economic signals are contributing to market uncertainty.

2026. g. 3. sept. 19:16 UTC

Biogen and Eisai received approval for LEQEMBI in China for early Alzheimer's treatment. Piper Sandler raised Biogen's price target to $245, maintaining an Overweight rating.

2026. g. 2. sept. 23:56 UTC

Biogen Inc shares are higher in after-market trading, despite no specific news. Broader market dynamics may be influenced by weaker ADP payrolls data.

2026. g. 1. sept. 21:01 UTC

Biogen Inc. shares are lower in after-market hours, continuing a downward trend over the past three sessions with no specific news identified.

2026. g. 31. aug. 19:46 UTC

Biogen Inc's shares are lower amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh at the Jackson Hole symposium.

2026. g. 28. aug. 21:01 UTC

Biogen Inc shares are lower in after-market hours, reflecting broader market weakness. No specific news was identified to explain the decline.

2026. g. 26. aug. 20:08 UTC

Biogen Inc. has chosen Veeva Systems' Veeva Vault CRM to enhance its digital strategy, with shares rising during Wednesday's session amid positive sentiment.

2026. g. 25. aug. 23:26 UTC

Biogen Inc. shares are trading roughly flat in after-market hours. Crude oil prices have declined, easing some geopolitical tensions, impacting overall market sentiment.

2026. g. 24. aug. 20:13 UTC

Biogen Inc shares are trading lower in after-market hours. Broader market conditions may be influencing trading sentiment amid U.S.-Iran tensions and inflation concerns.

2026. g. 21. aug. 20:06 UTC

Biogen Inc is trading higher since Thursday's close, reflecting positive market trends. The stock remains above its 20-day moving average despite a recent pullback.

2026. g. 20. aug. 20:01 UTC

Shares lower today amid broader market declines and ETF drop.

2026. g. 19. aug. 23:06 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Wednesday's close. The asset remains above its 20-day moving average.

2026. g. 17. aug. 19:46 UTC

Biogen Inc. shares are lower today amid routine trading, despite an unexpected rise in the New York manufacturing index supporting broader market conditions.

2026. g. 14. aug. 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting routine fluctuations. The stock remains above its 20-day moving average and near its monthly range high.

2026. g. 13. aug. 20:06 UTC

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

2026. g. 12. aug. 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

2026. g. 11. aug. 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.

2026. g. 10. aug. 19:36 UTC

Biogen Inc has completed its $1 billion acquisition of RayThera. Shares are trading lower despite the strategic development and potential pipeline enhancement.

2026. g. 7. aug. 23:16 UTC

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

2026. g. 6. aug. 23:11 UTC

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

2026. g. 5. aug. 19:26 UTC

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.

2026. g. 4. aug. 20:02 UTC

Mizuho raised its price target on Biogen Inc. to $241, contributing to the stock's upward movement during Tuesday's session.

2026. g. 3. aug. 23:06 UTC

Biogen Inc. shares are trading higher in after-market hours, supported by stronger-than-expected manufacturing data and positive broader market sentiment.

2026. g. 31. jūl. 21:01 UTC

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Shares are higher in after-market trading following the positive results and raised EPS guidance.

2026. g. 30. jūl. 19:39 UTC

Biogen Inc shares are lower in Thursday's session, reaching a low of approximately -2.86% earlier. No specific news was identified to explain the decline.

2026. g. 29. jūl. 22:02 UTC

Biogen Inc shares are higher in after-market hours, maintaining a steady upward trajectory since Wednesday's close and staying above the 20-day moving average.

2026. g. 28. jūl. 22:01 UTC

Biogen Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains above its 20-day moving average.

2026. g. 27. jūl. 18:56 UTC

Biogen Inc. shares are lower today amid routine trading fluctuations. Broader market declines are influenced by falling oil prices ahead of the Federal Reserve meeting.

2026. g. 24. jūl. 18:26 UTC

Biogen Inc. shares are higher today, continuing an upward trend since Thursday. The stock's movement appears independent of recent oil price volatility.

2026. g. 22. jūl. 22:01 UTC

Biogen Inc shares are trading higher in after-market hours, reflecting an increase since Wednesday's close amid broader market volatility and rising crude oil prices.